We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

30 hedge funds and large institutions have $174M invested in Crescent Biopharma in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,587% more capital invested

Capital invested by funds: $6.46M → $174M (+$167M)

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

16.18% more ownership

Funds ownership: 0.48% → 16.66% (+16%)

14% less funds holding

Funds holding: 35 → 30 (-5)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

Holders
30
Holders Change
-5
Holders Change %
-14.29%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
9
Reduced
5
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$29.9M
2
FFM
Fairmount Funds Management
Pennsylvania
+$29.4M
3
VA
VR Adviser
New York
+$28.7M
4
BI
BVF Inc
California
+$27.3M
5
PBA
Paradigm Biocapital Advisors
New York
+$13.6M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$561K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$120K
3
UBS Group
UBS Group
Switzerland
-$93.8K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$80.3K
5
SC
Shay Capital
New York
-$74.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$2.62K -$1.74K -82 -34%
SS
27
SBI Securities
Japan
$1.1K -$21 -1 -1%
Raymond James Financial
28
Raymond James Financial
Florida
$807 +$1.06K +50 New
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$65 -$21 -1 -20%
Vanguard Group
30
Vanguard Group
Pennsylvania
– -$561K -26,702 Closed
Geode Capital Management
31
Geode Capital Management
Massachusetts
– -$120K -5,717 Closed
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
– -$80.3K -3,826 Closed
SC
33
Shay Capital
New York
– -$74.9K -3,568 Closed
State Street
34
State Street
Massachusetts
– -$37.6K -1,793 Closed
Northern Trust
35
Northern Trust
Illinois
– -$24.6K -1,170 Closed
IP
36
Intellectus Partners
California
– -$9.65K -460 Closed
IC
37
IEQ Capital
California
– -$8.06K -384 Closed
VF
38
Virtu Financial
New York
– -$8K -363 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$6.42K -306 Closed
VPIM
40
Vanguard Personalized Indexing Management
California
– -$3.56K -169 Closed
TSS
41
Two Sigma Securities
New York
– -$3.31K -157 Closed
Millennium Management
42
Millennium Management
New York
– -$2.91K -139 Closed
PVI
43
Pine Valley Investments
New Jersey
– -$2.63K -125 Closed
1NWS
44
1 North Wealth Services
Maryland
– -$2.52K -120 Closed
FWP
45
Firethorn Wealth Partners
Georgia
– -$2.46K -117 Closed
HF
46
HRT Financial
New York
– -$2K -100 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– -$1.96K -94 Closed
TC
48
Truvestments Capital
Florida
– -$275 -13 Closed
JP Morgan Chase
49
JP Morgan Chase
New York
– -$26 -1 Closed
1
2

CBIO Hedge Fund Activity: Q2 2025 in Review

30 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2025, worth a combined $174M — up 2,587% from $6.46M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CBIO and 15 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 9 added.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $29.9M. The largest seller was Vanguard Group, exiting entirely with an estimated $561K sold.

  • 30 institutional investors held Crescent Biopharma (CBIO) as of Q2 2025, down from 35 in Q1 2025.
  • Funds reported $174M of Crescent Biopharma stock for Q2 2025, up 2,587% quarter-over-quarter.
  • 15 funds opened new Crescent Biopharma positions in Q2 2025 and 20 closed out, a net change of -5 holders.
  • The largest Crescent Biopharma buyer in Q2 2025 was Fidelity Investments, an estimated $29.9M added.
  • The largest Crescent Biopharma seller in Q2 2025 was Vanguard Group, an estimated $561K sold.

Based on aggregated 13F filings for Q2 2025.